Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval”In the company’s words, NCT07646587 on ClinicalTrials.gov
- Main trialPhase 2
- “This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)”In the company’s words, NCT07646587 on ClinicalTrials.gov
Other drugs for COPD (Chronic Obstructive Pulmonary Disease)
- TQC3721Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- EnsifentrineMerck & Co. · Nuance Pharma · Phase 3
- HSK39004Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- AstegolimabRoche · Phase 3
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- JKN2401Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3
Coming up2
- 17 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Oct 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 17 Dec 2027 | A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) | |
| Phase 2Recruiting | 1 Oct 2028 | Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026